View Older Stories View More Recent Stories
-
Cosmos Health Secures Additional 2.5 Million Units Under New Five-Year Contract Manufacturing Agreement with Viofar; Total Orderbook Surpasses 27.5 Million Units
-
Cosmos Health begins UK sales of veterinary antimicrobial C-ScrubVet
-
Cosmos Health Launches C-ScrubVet in the UK, Advancing into the $69 Billion Global Animal Health Market
-
Cosmos Health reports record revenue, retires debt early in 2026
-
Cosmos Health retires $8M convertible note a year early, buys back stock
-
Cosmos Health projects $6M in annual revenue from new olive supplement
-
Cosmos Health posts 29% revenue gain in Q2 but widens net loss
-
Cosmos Health develops AI subscription platform for consumer health products
-
Cosmos Health expands Albania distribution deal to 54,000 annual units
-
Cosmos Health signs 5-year deal to sell diabetes drug in Greece
-
Cosmos Health (COSM) Launches Subscription Model
-
Cosmos Health buys back 2.65M shares for $500K under new program
-
Cosmos Health files hydrogel weight loss patent in four markets
-
Cosmos Health antiseptic product nears $1.3M in annualized sales in Greece
-
Cosmos Health unit secures 25M-unit manufacturing orderbook
-
CosmoFarm posts record Q2 2026 revenue above $15M
-
Cosmos Health launches Korean collagen skincare line in the U.S.
-
Cosmos Health projects over $22.7M revenue from four US products
-
Cosmos Health reports $1.5m in antiseptic brand sales, eyes EU expansion
-
Cosmos Health reports record $65.3M revenue, targets $200M by 2029
-
Cosmos Health secures 5-year CERTORUN manufacturing deal worth 385,000 units
-
Cosmos Health (COSM) files $200M mixed shelf
-
Cosmos Health launches Oliv18 supplement in the US market
-
Cosmos Health expands Sky Premium Life to all 27 EU states via Skroutz
-
Cosmos Health identifies $20 million in non-core assets for potential sale
-
Cosmos Health discusses European Investment Bank financing talks
-
Cosmos Health enters animal health market with C-Scrub wash
-
Cosmos Health issues 2026-2029 guidance targeting $200m revenue by 2029
-
Cosmos Health lets 4.87 million Series B warrants expire unexercised
-
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants
-
Cosmos Health reports record Q1 revenue of $17.9 million, up 31%
-
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with
-
Cosmos Health secures advisory deal with European Investment Bank
-
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents
-
Cosmos Health withdraws SEC registration statement for public offering
-
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1
-
Cosmos Health projects $3.2M revenue from Fort18 supplement launch
-
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months
-
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed
-
Cosmos Health launches Fort18 supplement for men's sexual stamina in US
-
Cosmos Health Introduces Fort18 in the United States - A Men's Sexual Stamina Supplement Expanding the 18 Series into Men's Wellness
-
Cosmos Health projects $2.5 million revenue from Cur18 supplement
-
Cosmos Health Projects Over $2.5 Million in Incremental Annual Revenue from Cur18 in the United States Within 12-18 Months
-
Cosmos Health Introduces the "18 Series" in the United States - A Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting
-
Cosmos Health completes Liv18 development, eyes $5M annual revenue
-
Cosmos Health Accelerates U.S. Expansion: Liv18 Phase 1 Execution Complete; Production and Sales Commencing April 2026; Expected to Generate $5M+ in Annual Revenue at ~75% Gross Margins; Early U.S. Co
-
Cosmos Health plans US launch of enhanced curcumin supplement in Q2
-
Cosmos Health Continues US Expansion with Q2 Launch of Cur18 - a Clinically Studied, Patented Curcumin Next-Gen Therapy Supplement Delivering 39× Higher Bioavailability and Designed to Support Joint
-
Cosmos Health deploys AI across operations, targets 30% cost reduction
-
Cosmos Health Advances AI Investments to Enhance Efficiency, Reduce Costs, Improve Customer Experience and Drive Sales Growth; Certain Operating Expenses May Decrease by Up to 30%
